The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma.

Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther (2013) 1.04

Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther (2007) 0.88

Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation. Cancer Gene Ther (2008) 0.87

E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer. Dig Dis Sci (2008) 0.79

Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma. World J Gastroenterol (2006) 0.76

shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy. Oncotarget (2016) 0.75

The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res (2005) 0.75

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17

Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 3.86

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42

Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet (2012) 3.07

An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04

Comparison of plethysmographic and helium dilution lung volumes: which is best for COPD? Chest (2009) 2.98

Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63

Case scenario: acute postoperative negative pressure pulmonary edema. Anesthesiology (2010) 2.54

Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol (2007) 2.48

Health risk of chrysotile revisited. Crit Rev Toxicol (2013) 2.45

DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst (2005) 2.43

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther (2007) 2.14

CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol (2009) 2.11

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09

Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res (2007) 2.08

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol (2011) 2.06

Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther (2011) 1.96

Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91

Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (2014) 1.91

The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant (2005) 1.90

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res (2008) 1.89

Thrombocytopenia associated with chronic liver disease. J Hepatol (2008) 1.89

Asthma outcomes: biomarkers. J Allergy Clin Immunol (2012) 1.88

Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res (2007) 1.87

Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther (2003) 1.87

miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci U S A (2010) 1.83

Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis (2005) 1.77

CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett (2008) 1.75

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 1.74

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A (2008) 1.73

Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res (2002) 1.72

Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 1.70

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol (2005) 1.69

Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol (2008) 1.66

The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res (2004) 1.65

ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res (2003) 1.55

Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53

Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res (2012) 1.52

Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther (2010) 1.51

Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther (2002) 1.49

Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol (2006) 1.48

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol (2011) 1.48

Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47

Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer. Oncology (2009) 1.47

Progressive granulomatous pneumonitis in response to cosmetic subcutaneous silicone injections in a patient with HIV-1 infection: case report and review of the literature. Arch Pathol Lab Med (2012) 1.46

Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl (2009) 1.46

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecol Oncol (2007) 1.44

The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol (2004) 1.41

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res (2007) 1.40

90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer (2008) 1.39

Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat Chem Biol (2013) 1.38

Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36

Targeting tumor vasculature with an oncolytic virus. Mol Ther (2011) 1.35

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol (2003) 1.34

Ameloblastoma: a surgeon's dilemma. J Oral Maxillofac Surg (2006) 1.34

Recommendations for improved acute pain services: Canadian collaborative acute pain initiative. Pain Res Manag (2004) 1.33

ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res (2008) 1.33

Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat (2004) 1.32

Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther (2003) 1.31

HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res (2011) 1.28

Improved validation of peptide MS/MS assignments using spectral intensity prediction. Mol Cell Proteomics (2006) 1.28

DNA methylation as a long-term biomarker of exposure to tobacco smoke. Epidemiology (2013) 1.28

Update on tubulin-binding agents. Pathol Biol (Paris) (2006) 1.26

Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One (2007) 1.22

Spirometry testing standards in spinal cord injury. Chest (2003) 1.22

Antigenic diversity is generated by distinct evolutionary mechanisms in African trypanosome species. Proc Natl Acad Sci U S A (2012) 1.22

The role of targeted therapy in ovarian cancer. Eur J Cancer (2011) 1.20

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol (2013) 1.20

Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital. Eur J Cancer (2008) 1.20

Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res (2005) 1.20

Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis (2005) 1.17

Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res (2011) 1.15

The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer (2009) 1.15

Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res (2008) 1.14

Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.14

Genome screen to detect linkage to intracranial aneurysm susceptibility genes: the Familial Intracranial Aneurysm (FIA) study. Stroke (2008) 1.10

Determinants of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC in chronic spinal cord injury. Arch Phys Med Rehabil (2006) 1.09

Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev Mol Med (2004) 1.08

A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2007) 1.07

Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol (2005) 1.07

Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol (2002) 1.06

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther (2010) 1.05

Microcalorimetric study of ammonia chemisorption on H3PW12O40 supported onto mesoporous synthetic carbons and SBA-15. Langmuir (2006) 1.05

Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol (2005) 1.04

Clinical ventilator adjustments that improve speech. Chest (2003) 1.04

Growth of Rhodospirillum rubrum on synthesis gas: conversion of CO to H2 and poly-beta-hydroxyalkanoate. Biotechnol Bioeng (2007) 1.04

Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg (2005) 1.03

The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther (2002) 1.03

A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther (2008) 1.03

Declining expression of a single epithelial cell-autonomous gene accelerates age-related thymic involution. Aging Cell (2010) 1.03

High-throughput gene discovery in the rat. Genome Res (2004) 1.02

Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology (2013) 1.02

Diagnostic radiation exposure in pediatric trauma patients. J Trauma (2011) 1.02

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep (2011) 1.01